These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27269057)

  • 21. Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
    Pajon R; Fergus AM; Granoff DM
    PLoS One; 2013; 8(6):e66536. PubMed ID: 23805230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.
    Costa I; Pajon R; Granoff DM
    mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.
    Koeberling O; Seubert A; Santos G; Colaprico A; Ugozzoli M; Donnelly J; Granoff DM
    Vaccine; 2011 Jun; 29(29-30):4728-34. PubMed ID: 21571025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.
    Pinto VB; Moran EE; Cruz F; Wang XM; Fridman A; Zollinger WD; Przysiecki CT; Burden R
    Vaccine; 2011 Oct; 29(44):7752-8. PubMed ID: 21827811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
    Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
    Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.
    Pinto VB; Burden R; Wagner A; Moran EE; Lee CH
    PLoS One; 2013; 8(11):e79304. PubMed ID: 24244473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.
    Partridge E; Lujan E; Giuntini S; Vu DM; Granoff DM
    Vaccine; 2017 Jul; 35(33):4236-4244. PubMed ID: 28651840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of immunological responses to recombinant Porin A protein (rPoA) from native strains of Neisseria meningitidis serogroups A and B using OMV as an adjuvant in BALB/c mice.
    Afrough P; Bouzari S; Mousavi SF; Asadi Karam MR; Vaziri F; Fateh A; Behrouzi A; Malekan M; Siadat SD
    Microb Pathog; 2017 Nov; 112():209-214. PubMed ID: 28942175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
    Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
    Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
    Hou VC; Koeberling O; Welsch JA; Granoff DM
    J Infect Dis; 2005 Aug; 192(4):580-90. PubMed ID: 16028126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
    McNeil LK; Donald RGK; Gribenko A; French R; Lambert N; Harris SL; Jones TR; Li S; Zlotnick G; Vogel U; Claus H; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Wang X; Vuong J; Mayer LW; Pride MW; Jansen KU; Anderson AS
    mBio; 2018 Mar; 9(2):. PubMed ID: 29535195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterisation and Immunogenicity of
    Manoharan S; Farman TA; Piliou S; Mastroeni P
    Front Immunol; 2024; 15():1473064. PubMed ID: 39380985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
    Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
    Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.
    Rossi R; Konar M; Beernink PT
    Infect Immun; 2016 Jun; 84(6):1735-1742. PubMed ID: 27021245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.
    Giuntini S; Beernink PT; Granoff DM
    Vaccine; 2015 Dec; 33(51):7168-7175. PubMed ID: 26562320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?
    Granoff DM; Ram S; Beernink PT
    Clin Vaccine Immunol; 2013 Aug; 20(8):1099-107. PubMed ID: 23740919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
    Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
    Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.